The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
Author:
Affiliation:
1. Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Funder
None
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14740338.2017.1325871
Reference53 articles.
1. Cancer statistics, 2017
2. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
3. Ovarian cancer standard of care: are there real alternatives?
4. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer;American Journal of Clinical Oncology;2023-06-12
2. Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma;Cancers;2023-01-08
3. Advances in small molecule maintenance therapies for high-grade serous ovarian cancer;Expert Opinion on Pharmacotherapy;2022-12-12
4. Gestion pratique des inhibiteurs de PARP : Un consensus national DELPHI;Bulletin du Cancer;2022-12
5. Immunotherapy for platinum-resistant ovarian cancer;Gynecologic Oncology;2020-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3